Emily Tan
Jun 14, 2013

Pharma giant Merck settles US$600 million global media review

GLOBAL - Pharmaceutical company Merck is reported to have awarded media planning and buying duties in Asia-Pacific to ZenithOptimedia and to Havas Media in Europe and Latin America.

Pharma giant Merck settles US$600 million global media review

It was not clear at press time which agencies have won in other markets. 

The review, said to be worth US$600 million, was announced last October. It is believed to have involved incumbent agency Draftfcb, which held the company's media account in the US jointly with fellow Interpublic agency Initiative—which also held some of the business in Europe. 

Brands under Merck include Claritin, Dr. Scholl's and Coppertone.  

Media agencies contacted for this article refused to comment or could not be reached.  

 

 

 

Source:
Campaign Asia

Related Articles

Just Published

1 day ago

Alibaba pledges 'aggressive' AI investment, reports ...

Revenue jumped 8% as Alibaba's AI-driven strategy paid off. A surge in investor confidence has sent its share price soaring over 60% since the start of the year.

1 day ago

Five by Five Global to deliver AI-powered campaigns ...

Can creativity truly be compressed? Former Cheil Australia MD Mark Anderson, now at Five by Five Global, is betting big on AI with a new seven-hour sprint model to find out.

1 day ago

BBDO launches new global vision to focus on bolder ...

'Do Big Things' will empower brands to take risks, make noise, and tackle the world's biggest problems with bold solutions, says global CEO Nancy Reyes.

1 day ago

Is Elon Musk’s X winning back advertisers?

Social media platform X is reportedly in talks to raise money at its buying price valuation of $44 billion, despite user and advertiser losses since Elon Musk’s acquisition in 2022.